CNTX-4975

Phase 2Small molecule

CCentrexion Therapeutics

CNTX-4975 is one of 35 small molecule programs targeting Osteoarthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

NeuromaActive, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

NeuromaPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Ilaris

Novartis

Preclinical

2 2

Cataflam

Platelet Rich Plasma

25 4

CNTX-4975

CCentrexion Therapeutics

Phase 2

2 5

Enbrel

IImmunex

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Ansaid

PPharmacia and Upjohn

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroma2 trials

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Completed·CCentrexion Therapeutics·Phase 2·NCT02283957·119 enrolled

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Completed·CCentrexion Therapeutics·Phase 2·NCT02678793·67 enrolled

Osteoarthritis2 trials

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

Completed·CCentrexion Therapeutics·Phase 2·NCT00667654·54 enrolled

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Completed·CCentrexion Therapeutics·Phase 2·NCT02558439·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CNTX-4975. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CNTX-4975 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CNTX-4975. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centrexion Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentrexion Therapeutics

CNTX-4975

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroma2 trials

Osteoarthritis2 trials

References

Drug Info

Quick Facts

Related News